Biocon And Viatris Ready To Launch EU Bevacizumab

Biocon Biologics Announces Formal EU Approval For Abevmy Biosimilar

 
• By Dave Wallace

Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.

EU Europe Flag Biosimilar Vaccine
Biocon and Viatris have received formal EU approval for Abevmy • Source: Alamy

More from Biosimilars

More from Products